POS0976 Apremilast treatment in early oligoarticular psoriatic arthritis (PsA) improves clinical and patient-reported outcomes for up to 48 weeks - data from the Foremost study

Authors

L Gossec
LC Coates
Alvin Wells, Advocate Health - MidwestFollow
et al

Recommended Citation

Gossec L, Coates LC, Gladman DD, et al. POS0976 APREMILAST TREATMENT IN EARLY OLIGOARTICULAR PSORIATIC ARTHRITIS (PSA) IMPROVES CLINICAL AND PATIENT-REPORTED OUTCOMES FOR UP TO 48 WEEKS - DATA FROM THE FOREMOST STUDY. Annals of the Rheumatic Diseases. 2024;83:692-693.

Document Type

Abstract